

A COMPUTATIONAL DRUG DESIGNING FROM REPORTED ACTIVE PRODUCT OF *Andrographis paniculata* TO CURE HEPATIC TOXICITY

*Aubhishek Zaman**

Department of Genetic Engineering and Biotechnology, University of Dhaka,
Dhaka-1000, BANGLADESH

Corresponding author E mail: aubhishek@gmail.com

ABSTRACT

Andrographis paniculata (Kaalmegha) has long been used for hepatotoxicity according to ancient herbal practices. One of the major active products of the herbal plant is Silymarin. Silymarin consists of four flavonolignan isomers namely- silybin/silibinin, isosilybin, silydianin and silychristin. Here, the computational approach shows that silybin/silibinin binds to IGFBP3 and ALOX5, two major proteins that are upregulated as a body defense mechanism during liver damage. IGFBP3 is an IGF1 binding protein. IGF1 is involved in curing hepatotoxicity. On the contrary ALOX5 is an enzyme. Both the protein molecules can be potential targets of silibinin. Silibinin 3D structure was docked to the target proteins as a ligand. The scores for such docking was satisfactory. However, this conclusion should be subjected to further in vitro experiment as in biological system often that binds irreversibly is not the best effector. In final analysis, satisfactory binding scores explain a novel mechanism of how silibinin may act to cure hepatic toxicity. This research, although was focused to find the target of the afore-mentioned ligand, in the future may pave the way for a synthetic drug. It should also boost our confidence on herbal practices and thereby link a bridge between traditional and modern treatment techniques.

KEYWORDS

Andrographis paniculata, IGFBP3, ALOX5, Silymarin, Molecular Docking.

1 INTRODUCTION

Silymarin, a flavonolignan plant is used almost exclusively for hepatoprotection (Colturato, Constantin et al, Salamone, Galvano et al.). The use of silymarin may replace the polyherbal formulations and will avoid the major problems of standardization, quality control and contamination with heavy metals or bacterial toxins (Girish 2006). Silymarin consists of four flavonolignan isomers namely- silybin, isosilybin, silydianin and silychristin. Among them,

silybin/silibinin is the most active and commonly used form. Silymarin is orally absorbed and is excreted mainly through bile as sulphates and conjugates. Silymarin offers good protection in various toxic models of experimental liver diseases in laboratory animals (Haddad, Vallerand et al. 2009). It acts by antioxidative, anti-lipid peroxidative, antifibrotic, anti-inflammatory, membrane stabilizing, immunomodulatory and liver regenerating mechanisms. Silymarin has clinical applications in

alcoholic liver diseases, liver cirrhosis, Amanita mushroom poisoning, viral hepatitis, toxic and drug induced liver diseases and in diabetic patients (Hruby, Csomos et al. 1983; Vogel, Tuchweber et al. 1984; Dehmlow, Erhard et al. 1996; von Schonfeld, Weisbrod et al. 1997). Though silymarin does not have antiviral properties against hepatitis virus (Ahmed-Belkacem, Ahnou et al. ; Dahari, Guedj et al. ; Eurich, Bahra et al. ; Neumann, Biermer et al.), it promotes protein synthesis, helps in regenerating liver tissue, controls inflammation (Zi, Zhang et al. 2000; Cheung, Taylor et al. 2007; Wang, Tashiro et al. 2008), enhances glucuronidation and protects against glutathione depletion (Lin, Sukarieh et al. 2009). Silymarin may prove to be a useful drug for hepatoprotection in hepatobiliary diseases and in hepatotoxicity due to drugs. The nontraditional use of silymarin may make a breakthrough as a new approach to protect other organs in addition to liver (Singh and Agarwal 2006; Cheung, Vesey et al. 2007; Singh, Deep et al. 2007; Jung, Park et al. 2009; Kim, Kim et al. 2009). As it is having a good safety profile, better patient tolerability and an effective drug at an affordable price, in near future new derivatives or new combinations of this drug may prove to be useful (Kim, Kim et al. 2003; Tyagi, Agarwal et al. 2003).

The Insulin-like growth factor-binding protein also known as IGFBP serves as a carrier protein for Insulin-like growth factor 1 (IGF-1). IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. It is also reported to Interacts with XLKD1 and bind IGF2 more than IGF1 and thereby forms a ternary complex of about 140 to 150 kDa with IGF1 or

IGF2 and a 85 kDa glycoprotein ALS named Insulin-like Growth Factor Acid-labile Subunit (IGFALS). It is expressed by most tissues and also present in plasma. One key observation is that IGFBP3 levels are higher during extra-uterine life and it elevates during puberty (Cubbage, Suwanichkul et al. 1990; Jasper, Pennisi et al. 1999).

IGFBP3 gene is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

IGFBP3 protein levels decrease during the progression of prostate cancer from benign prostatic hyperplasia (BPH) to its metastatic form (Natsuzaka, Naganuma et al.; Regel, Eichenmuller et al. ; Wu, Buckner et al.). But, production of the protein does not cease completely. IGFBP3 is still made (at a lower level) by prostate cancer cells and secreted into the surrounding environment (Schildkraut, Demark-Wahnefried et al. 2005; Povelitsa 2007). However, instead of the full length, functional protein, IGFBP3 is found to be cleaved. This prevents IGFBP3 from binding and sequestering IGFs and the growth factors are free to bind the IGF-1R and promote cell survival

Approximately 98% of IGF-1 is always bound to one of six binding proteins (IGF-BP). IGFBP3, the most abundant protein, accounts for 80% of all IGF binding protein. IGF-1 binds to IGFBP3 in a 1:1 molar ratio. IGF-BP also binds to IGF-1 inside the liver, allowing growth hormone to continuously act upon the liver to produce more

IGF-1. This is important because proliferating IGF-1 + IGF-BP complex allow growth of the hepatic cells (Cubbage, Suwanichkul et al. 1990; Lovett-Racke, Bittner et al. 1998; Jasper, Pennisi et al. 1999).

Arachidonate 5-lipoxygenase, also known as 5-lipoxygenase or 5-LO, is an enzyme that in humans is encoded by the ALOX5 gene. Arachidonate 5-lipoxygenase is a member of the lipoxygenase family of enzymes (Kennedy, Diehl et al. 1991; Kim, Choi et al. 2005; Chen, Li et al. 2009). It transforms essential fatty acids into leukotrienes and is a current target for pharmaceutical intervention in a number of diseases. 5-LO catalyzes oxidation of AA (arachidonic acid) at the 5-position to yield 5-hydroperoxyeicosatetraenoic acid (5-HPETE). 5-LO then converts 5-HPETE to leukotriene A4. Two other lipoxygenases, 12-LO and 15-LO, act at the 12- and 15-positions, yielding 12- and 15-HPETE. These pathways lead to the leukotriene 12-hydroxyeicosatetraenoic acid (12-HETE) and to the lipoxins, respectively (KEGGPathwayDatabase).

This gene encodes a member of the lipoxygenase gene family and plays a dual role in the synthesis of leukotrienes from arachidonic acid (Funk, Hoshiko et al. 1989; Hoshiko, Radmark et al. 1990; Samuelsson, Hoshiko et al. 1991). The encoded protein, which is expressed specifically in bone marrow-derived cells, catalyzes the conversion of arachidonic acid to 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid, and further to the allylic epoxide 5(S)-trans-7,9-trans-11,14-cis-eicosatetraenoic acid (leukotriene A4) (Kim, Choi et al. 2005; Manev and Manev 2006).

Leukotrienes are important mediators of a number of inflammatory and allergic conditions. Mutations in the promoter region of this gene lead to a diminished response to antileukotriene drugs used in the treatment of asthma and may also be associated with atherosclerosis and several cancers. Alternatively spliced transcript variants encoding different isoforms have been found for this gene (Kim, Choi et al. 2005).



FIGURE 1: *Andrographis paniculata* plant. The plant is found in Sylhet district in Bangladesh. The herbaceous plant has distinctive white flowers.

Andrographis paniculata is a herbaceous plant in the family *Acanthaceae*, native to Bangladesh and India (Alagesaboopathi, Diwakaran et al. 1999; Zhang 2000; Alagesaboopathi, Dwarakan et al. 2001). It is widely used as a cardiac and (Awang, Abdullah et al. ; Nagalekshmi, Menon et al.) hepatoprotective agent (Nagalekshmi, Menon et al. ; Ojha, Bharti et al. ; Ojha, Bharti et al. ; Handa and Sharma 1990; Balu and Alagesaboopathi 1993; Kapil, Koul et al. 1993; Puri, Saxena et al. 1993; Panossian, Hovhannisyan et al. 2000; Singh, Banerjee et al. 2001; Trivedi and Rawal 2001; Sheeja and Kuttan 2006). Mostly the leaves and roots were used for medicinal Purposes as Hepatoprotective, cholinergic, antispasmodic, stomachic, anthelmintic, alterative, blood purifier and febrifuge agent.(Chao, Kuo et al. ; Chien, Wu et al. ; Chao, Kuo et al. 2009). It acts well on the liver, promoting secretion of bile. It is used in jaundice and torpid liver, flatulence and diarrhoea of children, colic, strangulation of intestines and splenomegaly; also for cold and upper respiratory tract infections (Sulaiman, Zakaria et al. ; Mandal, Dhara et al. 2001; Geethangili, Rao et al. 2008; Burgos, Hancke et al. 2009; Chandrasekaran, Thiyagarajan et al. 2009; Das, Gautam et al. 2009; Lin, Wu et al. 2009; Pekthong, Blanchard et al. 2009; Rattanachaikunsopon and Phumkhachorn 2009). It is also known as Kaalmegha locally.

Kaalmegha dried leaves and tender shoots yield not less than 1% andrographolide on dry-weight basis (Chakravarti and Chakravarti 1951; Rajani, Shrivastava et al. 2000). Several active constituents have been identified from the leaf and rhizome, including andrographolide, deoxyandrographolide and other diterpenes (Chao and Lin ; Jayaprakasam, Gunasekar et al. 2001; Rao, Harikishore et al. 2002; Kesava Reddy, Vijaya Bhaskar Reddy et al. 2003; Kesava Reddy,

Vijaya Bhaskar Reddy et al. 2003; Qizhen, Jerz et al. 2003; Rao, Damu et al. 2003; Koteswara Rao, Vimalamma et al. 2004; Kumar, Sridevi et al. 2004; Pholphana, Rangkadilok et al. 2004; Chen, Qu et al. 2006). Andrographolide exhibited strong choleric action when administered intraperitoneally (i.p.) to rats. It induces increase in bile flow together with change in physical properties of bile secretion. It was found to be more potent than silymarin. Andrographolide was found to be almost devoid of antihepatitis-B virus surface antigen-like activity (Chandrasekaran, Gupta et al; Maiti, Mukherjee et al. ; Singha, Roy et al. 2003). The leaf and stem extracts of Kaalmegha andrographolide given subcutaneously (s.c.) or orally did not change blood sugar level of normal or diabetic rats (Akbar; Pan, Abd-Rashid et al.; Parichatikanond, Suthisisang et al. ; Borhanuddin, Shamsuzzoha et al. 1994; Zhang, Tang et al. 1994; Zhang and Tan 2000; Zhang and Tan 2000).

Alcoholic extract of the plant exhibited antidiarrhoeal activity against *E. coli* enterotoxins in animal models (Mishra, Mishra et al. 2009). Clinical evidence of effectiveness of andrographis in humans is limited to the common cold. Preliminary evidence suggests that it might increase antibody activity and phagocytosis by macrophages, and might have mast cell-stabilizing and antiallergy activity. (Natural Medicines Comprehensive Database, 2007) The herb is contraindicated in bleeding disorders (Wang and Zhao 1994; Sheeja, Guruvayoorappan et al. 2007; Liu, Wang et al. 2008; Verma and Vinayak 2008), hypotension (Reyes, Bautista et al. 2006; Yooan, Thisoda et al. 2007; Neogy, Das et al. 2008), as well as male and female sterility (exhibited activity against infertility in laboratory animals)(Mkrtchyan, Panosyan et al. 2005). Whole plant juice is taken at a dose of 5–10 ml;

50–100 ml decoction; 1–3 g powder (Li, Zhou et al. ; Xu and Wang).

AutoDock is a suite of automated docking tools. It is designed to predict how small molecules, such as substrates or drug candidates, bind to a receptor of known 3D structure (Cosconati, Forli et al. ; Goodsell, Morris et al. 1996; Morris, Huey et al. 2008. Current distributions of AutoDock consist of two generations of software: AutoDock 4 and AutoDock Vina. AutoDock 4 actually consists of two main programs: autodock performs the docking of the ligand to a set of grids describing the target protein; autogrid pre-calculates these grids (Seeliger and de Groot ; Goodsell 2009). In addition to using them for docking, the atomic affinity grids can be visualised. This can help, for example, to guide organic synthetic chemists design better binders (Tiwari, Mahasenan et al. 2009). AutoDock Vina does not require choosing atom types and pre-calculating grid maps for them. Instead, it calculates the grids internally, for the atom types that are needed, and it does this virtually instantly.

PatchDock

(<http://bioinfo3d.cs.tau.ac.il/PatchDock/>) is a computational tool for determining protein ligand or protein protein interaction (Schneidman-Duhovny, Inbar et al. 2005). Its algorithm is based on object recognition and image segmentation techniques used in Computer Vision. It actually mimics human vision and extracts image data from protein structure files such as in .pdb file extension. Docking can be compared to assembling a jigsaw puzzle. When solving the puzzle it is tried to match two pieces by picking one piece and searching for the complementary one (Mashiach, Schneidman-Duhovny et al.). A puzzle-solver concentrates on the patterns that are unique for the puzzle

element and look for the matching patterns in the rest of the pieces. PatchDock employs a similar technique. Given two molecules, their surfaces are divided into patches according to the surface shape. These patches correspond to patterns that visually distinguish between puzzle pieces. Once the patches are identified, they can be superimposed using shape matching (Schneidman-Duhovny D 2003).

Pocket-Finder

(<http://www.modelling.leeds.ac.uk/pocketfinder/>), an online computational tool to predict active site within a structure, is based on the Ligsite algorithm written by Hendlich *et al.* (Huang and Zou 2006; Huang and Zou 2006). Pocket-Finder was written to compare Geometric shape complementarity pocket detection with our new ligand binding site detection algorithm Q-SiteFinder.

REACTOME (<http://www.reactome.org/>) is an open-source, open access, manually curated and peer-reviewed pathway database (Croft, O'Kelly et al.; Stein 2004). Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. These include NCBI Entrez Gene, Ensembl and UniProt databases, the UCSC and HapMap Genome Browsers, the KEGG Compound and ChEBI small molecule databases, PubMed, and Gene Ontology. The rationale behind Reactome is to convey the rich information in the visual representations of biological pathways familiar from textbooks and articles in a detailed, computationally accessible format. The core unit of the Reactome data model is the reaction. Entities (nucleic acids, proteins, complexes and small molecules) participating in reactions form a network of biological interactions and are grouped into pathways. Examples of biological

pathways in Reactome include signaling, innate and acquired immune function, transcriptional regulation, translation, apoptosis and classical intermediary metabolism.

STRING 9.0 (Search Tool for the Retrieval of Interacting Genes/Proteins) database (<http://string-db.org/>) (Szklarczyk, Franceschini et al.) is an online public database where data are deposited from experimental as well as predicted sources. For a system understanding annotation of all the proteins are an absolute necessity. However, public efforts to collect and present protein interaction information have struggled to keep up with the pace of interaction discovery, partly because protein-protein interaction information can be error-prone and require considerable effort to annotate. STRING provides uniquely comprehensive coverage and ease of access to both experimental as well as predicted interaction information. Interactions in STRING are provided with a confidence score, and accessory information such as protein domains and 3D structures is made available, all within a stable and consistent identifier space. New features in STRING include an interactive network viewer that can cluster networks on demand, updated on-screen previews of structural information including homology models, extensive data updates and strongly improved connectivity and integration with third-party resources.

ChemDB (<http://cdb.ics.uci.edu/>) (Jonathan H. Chen 2007) is a chemical database with readily downloadable structures in pdb file format. It contains millions of commercially available small molecules, important for use as synthetic building blocks, probes in systems biology and as leads for the discovery of drugs and other useful compounds. The data is publicly available over the web for download and for targeted searches

using a variety of powerful methods. The chemical data includes predicted or experimentally determined physicochemical properties, such as 3D structure, melting temperature and solubility. Recent developments include optimization of chemical structure (and substructure) retrieval algorithms, enabling full database searches in less than a second. A text-based search engine allows efficient searching of compounds based on over 65M annotations from over 150 vendors. When searching for chemicals by name, fuzzy text matching capabilities yield productive results even when the correct spelling of a chemical name is unknown, taking advantage of both systematic and common names. Finally, built in reaction models enable searches through virtual chemical space, consisting of hypothetical products readily synthesizable from the building blocks in ChemDB.

Swiss-PdbViewer (DeepView) (<http://spdbv.vital-it.ch/>) (Guex and Peitsch 1997) is an application that provides a user friendly interface allowing to analyze several proteins at the same time. The proteins can be superimposed in order to deduce structural alignments and compare their active sites or any other relevant parts. Amino acid mutations, H-bonds, angles and distances between atoms are easy to obtain thanks to the intuitive graphic and menu interface.

PROCHECK (<http://www.ebi.ac.uk/thornton-srv/software/PROCHECK/>) (Laskowski, Rullmann et al. 1996) checks the stereochemical quality of a protein structure, producing a number of PostScript plots analysing its overall and residue-by-residue geometry. It includes PROCHECK-NMR for checking the quality of structures solved by NMR.

I-TASSER

(<http://zhanglab.ccmb.med.umich.edu/I-TASSER/>)(Roy, Kucukural et al. ; Zhang 2008) server is an Internet service for protein structure and function predictions. 3D models are built based on multiple-threading alignments by LOMETS and iterative TASSER assembly simulations; function insights are then derived by matching the predicted models with protein function databases. CPHmodels 3.2 is a protein homology modeling server. The template recognition is based on profile-profile alignment guided by secondary structure and exposure predictions. (Ambrish Roy 2011) (<http://www.cbs.dtu.dk/services/CPHmodels/>)(Nielsen, Lundegaard et al. 2010)

2. METHOD

2.1 Determining Interacting macromolecule

Interacting macromolecule has been predicted by using Small molecule-Protein interaction database named STITCH 3.1 (Search Tool for Interactions of Chemicals) (<http://stitch.embl.de/>) (Kuhn, von Mering et al. 2008). Protein to Protein interaction network was established using **STRING 9.0** (Search Tool for the Retrieval of Interacting Genes/Proteins) database (<http://string-db.org/>) (Szklarczyk, Franceschini et al.)

Protein to Protein interaction can further be confirmed by screening for binding informations in Database of Interacting Protein (DIP). Pathways associated to the proteins were viewed at Reactome database (<http://www.reactome.org/>).

Binding motifs can be searched by MotifFinder online tool. The tool retrieves interaction motifs in the proteins.

Toxnet database gives us gene up or downregulation information which facilitate choosing the target macromolecule.

2.2 Computational docking

The macromolecule structures were simulated ab initio using Protein 3D structure is the best indicator of the function as only this gives good account of how protein in native conformation behaves in vivo in biologically significant microenvironment. 3D structure was generated using **I-TASSER** (Roy, Kucukural et al. 2010) and **CphModel3.0** (Nielsen, Lundegaard et al. 2010).

The 3D Ligand structure was downloaded from online database ChemDB (<http://cdb.ics.uci.edu/>) and was subsequently docked to protein 3D structure of the macromolecule.

Ligand and macromolecule was docked using two programs- AutoDock Vina (Download link: <http://vina.scripps.edu/download.html>) and online tool PATCHDOCK (<http://bioinfo3d.cs.tau.ac.il/PatchDock/>).

2.3 Prediction analysis

Prediction of the structures were confirmed by online tool QMEAN, Swiss PDB Viewer (SPDV 4.0) and PROCHECK. The best 3D structure was selected on the basis of Ramachandran plot and Model quality Z-score. The best macromolecule structure was selected for docking with the downloaded ligand molecule.

The ligand bound protein structures provided by PATCHDOCK were viewed by RasWin and PyMol. The AutoDock results were analyzed using AutoDock tools -1.5.6rc3 and PyMol.

Protein pockets, candidates for ligand binding sites, were found by Pocket-Finder. The Pocket-

Finder tool results were screened with similar results found from binding. Thus this step can be

viewed as a confirmatory step for the binding results.

3. RESULTS

3.1 Determination of Interacting macromolecule

The STITCH 3.1 database predicted multiple interaction macromolecules for Silibinin. From the interaction diagram we can see that it is somehow associated with a special type of Cytochrome P-450 (CYP3A4), Tumor suppressor protein P53, Cell signaling protein CDK4 and CDK2 and some more (**FIGURE 4 and 5**). The result indicates that this small molecule may have important roles as a cancer drug (Fan, Qi et al. ; Fan, Yu et al. ; Wang, Ye et al. ; Zhang, Li et al. ; Agarwal, Singh et al. 2003; Tyagi, Agarwal et al. 2003) and rightly so as it has been proved to be very effective against hepatocellular carcinoma (HCC).

However the interaction does not gives us clear information regarding the binding pattern of the small molecule and subsequent signal transduction (**FIGURE 3**). To estimate binding of the molecules we needed to perform the docking experiment.

CTD data for silibinin retrieved up and downregulation gene information but failed to put insight into protein binding information (**FIGURE 2**). Following are the genes with maximum confidence whose expression is changed due to silibinin administration- ABCB11, AKR1C3, ATM, BAX, BCL2, BID, CASP2, CASP3, CASP8.

Related Genes:

Gene:	ABCB11 [Link to main CTD database]
Organism:	Rattus norvegicus
Interaction Type:	affects activity affects localization
Interaction:	silybin affects the localization of and affects the activity of ABCB11 protein
Synonyms:	ABC16 ABC member 16, MDR/TAP subfamily ATP-binding cassette, subfamily B (MDR/TAP), member 11 ATP-binding cassette sub-family B member 11 ATP-binding cassette, sub-family B, member 11 bile salt export pump BOS_1671 BRIC2 Bsep BSEP/SPGP Lith1 liver bile salt export pump PFIC2 PFIC-2 PGY4 progressive familial intrahepatic cholestasis 2 RP23-451M16.2 sister of P-glycoprotein sister p-glycoprotein SPGP
PubMed References:	(1)15763547

FIGURE 2: Screenshot of the CTD result. CTD retrieves gene expression information. Given above is an example screenshot.

Binding motifs can be searched by MotifFinder online tool. The tool retrieves interaction motifs in the proteins. Based on literature information and MotifFinder results 2 proteins were selected as potential target. They are- Arachidonate 5-lipoxygenase (ALOX5) and Insulin-like growth factor-binding protein 3 (IGFBP3).




FIGURE 3: IGFB3 Reactome result: The working mechanism of the protein IGFBP3 was retrieved from interactome database Reactome. The marked in green box represents IGFBP3’s position amidst the cellular system. The network seen here has the parent node named ‘Diabetes disease’.

From the network databases it was clear that these two proteins play important roles in relieving hepatocellular toxicity. Insulin like Growth Factor (IGF-1) is produced primarily by the liver as an endocrine hormone as well as in target tissues in a paracrine/autocrine fashion. However, the hypothesis that IGF-1 stimulation is triggered by the drug could only be proven by docking experiment.





FIGURE 4: STITCH 3.1 results: The interactions are viewed in three different modes. Top left one is the confidence view and the top right one represents the action view. The bottom one represents the evidence view. For IGFBP3 some activation evidences are available. However ALOX5 relationship was left out unannotated.

IGFBP3 seems to interact with few more proteins whereas ALOX5 is more concerned with enzymatic reactions instead of binding. Both the roles are important in case of curing hepatotoxicity.



Your Input:

silibinin Silibinin, also known as silybin, is the major active constituent of silymarin, the mixture of flavonolignans extracted from milk thistle (*Silybum marianum*) consisting of silibinin A and B, isosilibinin A and B, silicristin and silidianin. Both in vitro and animal research suggest that silibinin has hepatoprotective (antihepatotoxic) properties that protect liver cells against toxins. (482.4 g/mol) (*Homo sapiens*)

Predicted Functional Partners:

		Neighborhood	Gene Fusion	Cooccurrence	Coexpression	Experiments	Databases	Textmining	[Homology]	Score
CYP3A4	cytochrome P450, family 3, subfamily A, polypeptide 4; Cytochromes P450 are a group of heme-thi [...]									0.991
CDKN1B	cyclin-dependent kinase inhibitor 1B (p27, Kip1); Important regulator of cell cycle progression [...]									0.970
CCND1	cyclin D1; Essential for the control of the cell cycle at the G1/S (start) transition (295 aa)									0.965
CDK4	cyclin-dependent kinase 4; Probably involved in the control of the cell cycle (303 aa)									0.961
CDK2	cyclin-dependent kinase 2; Involved in the control of the cell cycle. Interacts with cyclins A, [...]									0.958
CCNB1	cyclin B1; Essential for the control of the cell cycle at the G2/M (mitosis) transition (433 aa)									0.952
TP53	tumor protein p53; Acts as a tumor suppressor in many tumor types; induces growth arrest or apo [...]									0.945
BIRC5	baculoviral IAP repeat-containing 5; Component of the chromosomal passenger complex (CPC), a co [...]									0.935
ALOX5	arachidonate 5-lipoxygenase; Catalyzes the first step in leukotriene biosynthesis, and thereby [...]									0.932
IGFBP3	insulin-like growth factor binding protein 3; IGF-binding proteins prolong the half-life of the [...]									0.919

FIGURE 5: STRING 9.0 Results: The interactions are viewed expanding the protein network for better insight into the drug action. ALOX5 did not parented any nodes even in the expanded mode. That gives rise to two possibilities; one is that it is a poor target, the other one is that it is a special case target that works as a ‘magic bullet’ during special conditions such as liver toxicity. The later one seemed to be the case after the final analysis.




FIGURE 6: Ligand Structures as downloaded from the Databases: 3D structures of the ligands- the structure of Silibinin in two different conformations.

3.2 Computational Prediction

The ligands (FIGURE 6) were docked to the proteins using two docking tools AutoDock and PATCHDOCK. PATCHDOCK gave the following results for solution 1 and 4 for ALOX5- (Table 1)

Table 1: PATCHDOCK results for docking with ALOX5

Solution	Score	Area	ACE	Transformation
1	6354	719.70	-131.89	-1.86 -0.87 -0.30 0.91 -18.09 -9.73
4	5842	745.60	-232.93	-2.52 -0.37 -1.08 -1.15 -8.99 -4.89

Rank	Solution Number	Global Energy	Attractive VdW	Repulsive VdW	ACE	HB
		↓				
1	4	-63.26	-31.66	8.31	-14.11	0.00
2	3	-59.35	-24.58	4.28	-16.37	0.00

Following are the results for IGFBP3- (Table 2)

Table 2: PATCHDOCK results for docking with IGFBP3

Solution	Score	Area	ACE	Transformation
1	7990	1084.60	-407.31	-0.23 1.08 -1.59 -8.54 8.17 -14.99
2	7836	944.00	-277.01	0.35 -0.62 2.50 59.33 10.92 -10.04

Rank	Solution Number	Global Energy	Attractive VdW	Repulsive VdW	ACE	HB
		↓				
1	1	-68.90	-31.48	22.23	-25.30	0.00
2	3	-62.80	-27.70	10.03	-18.94	0.00

Following are the Solutions and their corresponding binding scores (Binding affinity in Kcal/mol, RMSD upper and lower cut) for AutoDock for ALOX5- (Table 3)

Table 3: AutoDock results for Silybin-ALOX5 binding

Ligand	Binding Affinity	rmsd/ub	rmsd/lb
Silibinin (conformation1)	-9.2	0	0
Silibinin (conformation2)	-8.9	9.662	5.865
Silibinin (conformation3)	-8.8	9.985	5.5
Silibinin (conformation4)	-8.3	39.865	34.269
Silibinin (conformation5)	-8.2	41.031	37.613
Silibinin (conformation6)	-8	37.21	34.141
Silibinin (conformation7)	-7.8	40.883	35.545
Silibinin (conformation8)	-7.8	28.25	24.548
Silibinin (conformation9)	-7.8	42.605	36.524

Following are the Solutions and their corresponding binding scores (Binding affinity in Kcal/mol, RMSD upper and lower cut) for AutoDock for IGFBP3- (Table 4) (FIGURE 7, 8, 9 and 10)

Table 4: AutoDock results for Silybin-IGFBP3 binding

Ligand	Binding Affinity	rmsd/ub	rmsd/lb
Silibinin (conformation1)	-8.1	0	0
Silibinin (conformation2)	-7.7	5.531	2.907
Silibinin (conformation3)	-7.4	62.518	59.188
Silibinin (conformation4)	-7.3	3.222	1.689
Silibinin (conformation5)	-7.1	30.248	26.748
Silibinin (conformation6)	-7.1	9.971	1.806
Silibinin (conformation7)	-7.1	29.515	25.831
Silibinin (conformation8)	-7	10.839	3.095
Silibinin (conformation9)	-6.9	31.057	27.974




FIGURE 7: Best binding conformation of the ligand: At the left the binding conformation of the silibinin ligand after binding to ALOX5 is portrayed. At the right the binding conformation of the ligand is represented with IGFBP3 protein in a wireframe structure with residue labelling.




FIGURE 8: Ligand bound to the binding site in IGFBP3: Molecular surface of the protein IGFBP3 is marked in blue. The ligand (marked in green and red) is bound to the binding site.




FIGURE 9: Ligand bound to the binding site in ALOX5: Molecular surface of the **protein ALOX5** is marked in cocoa color. The ligand (marked in green and red) is bound to the binding site.




FIGURE 10: Ligand Binding to ALOX5 as viewed by RasWin. Ligand bound to the binding site is marked in Stick representation in yellow (top right and left, circled in black dotted lines). Ligand (marked in red, bottom) protrudes the protein structure to a good extent.

PocketFinder computational tool was used to find active site within the protein structure. Although the tool gives positive results for few potential active site, only the predicted site 1 in both the cases (FIGURE 11 AND 12) shows significance within confidence interval. The active site correlates excellently to the one cleft where ligand binds. Thus, it confirms tight binding of the ligand in the exact groove where predicted by docking tools as both the results correlates well to each other.

<p>Site 1 <input checked="" type="checkbox"/></p> <p>Site 2 <input type="checkbox"/></p> <p>Site 3 <input type="checkbox"/></p> <p>Site 4 <input type="checkbox"/></p> <p>Site 5 <input type="checkbox"/></p> <p>Site 6 <input type="checkbox"/></p> <p>Site 7 <input type="checkbox"/></p> <p>Site 8 <input type="checkbox"/></p> <p>Site 9 <input type="checkbox"/></p> <p>Site 10 <input type="checkbox"/></p> <p>Help! Download Start Again</p>	<p style="text-align: center;">Site Info:</p> <p>Predicted site 1</p> <p>Site Volume: 2788 Cubic Angstroms</p> <p>Protein Volume: 64976 Cubic Angstroms</p> <p style="text-align: center;">Binding Box Around Selected Sites</p> <p>Min Coords: (-24, -21, -36) Max Coords: (17, 13, 10)</p>	<p style="text-align: center;">Residues:</p> <table border="0"> <tr><td>75</td><td>CA</td><td>GLY</td><td>A</td><td>11</td></tr> <tr><td>76</td><td>C</td><td>GLY</td><td>A</td><td>11</td></tr> <tr><td>78</td><td>N</td><td>SER</td><td>A</td><td>12</td></tr> <tr><td>80</td><td>CB</td><td>SER</td><td>A</td><td>12</td></tr> <tr><td>82</td><td>C</td><td>SER</td><td>A</td><td>12</td></tr> <tr><td>84</td><td>N</td><td>GLN</td><td>A</td><td>13</td></tr> <tr><td>87</td><td>CG</td><td>GLN</td><td>A</td><td>13</td></tr> <tr><td>88</td><td>CD</td><td>GLN</td><td>A</td><td>13</td></tr> <tr><td>89</td><td>OE1</td><td>GLN</td><td>A</td><td>13</td></tr> <tr><td>90</td><td>NE2</td><td>GLN</td><td>A</td><td>13</td></tr> <tr><td>520</td><td>CD2</td><td>LEU</td><td>A</td><td>67</td></tr> <tr><td>641</td><td>OD1</td><td>ASP</td><td>A</td><td>80</td></tr> <tr><td>657</td><td>C</td><td>TRP</td><td>A</td><td>81</td></tr> <tr><td>658</td><td>O</td><td>TRP</td><td>A</td><td>81</td></tr> <tr><td>659</td><td>N</td><td>TYR</td><td>A</td><td>82</td></tr> <tr><td>660</td><td>CA</td><td>TYR</td><td>A</td><td>82</td></tr> </table>	75	CA	GLY	A	11	76	C	GLY	A	11	78	N	SER	A	12	80	CB	SER	A	12	82	C	SER	A	12	84	N	GLN	A	13	87	CG	GLN	A	13	88	CD	GLN	A	13	89	OE1	GLN	A	13	90	NE2	GLN	A	13	520	CD2	LEU	A	67	641	OD1	ASP	A	80	657	C	TRP	A	81	658	O	TRP	A	81	659	N	TYR	A	82	660	CA	TYR	A	82
75	CA	GLY	A	11																																																																														
76	C	GLY	A	11																																																																														
78	N	SER	A	12																																																																														
80	CB	SER	A	12																																																																														
82	C	SER	A	12																																																																														
84	N	GLN	A	13																																																																														
87	CG	GLN	A	13																																																																														
88	CD	GLN	A	13																																																																														
89	OE1	GLN	A	13																																																																														
90	NE2	GLN	A	13																																																																														
520	CD2	LEU	A	67																																																																														
641	OD1	ASP	A	80																																																																														
657	C	TRP	A	81																																																																														
658	O	TRP	A	81																																																																														
659	N	TYR	A	82																																																																														
660	CA	TYR	A	82																																																																														




FIGURE 11: Pocket-Finder results for surface cleft identification of ALOX5. Binding site of the ligand), as predicted by the tool. The cleft colored in cyan shows a significant pocket. This pocket correlates well with the binding site as predicted by the docking tools.

<p>Site 1 <input checked="" type="checkbox"/></p> <p>Site 2 <input type="checkbox"/></p> <p>Site 3 <input type="checkbox"/></p> <p>Site 4 <input type="checkbox"/></p> <p>Site 5 <input type="checkbox"/></p> <p>Site 6 <input type="checkbox"/></p> <p>Site 7 <input type="checkbox"/></p> <p>Site 8 <input type="checkbox"/></p> <p>Site 9 <input type="checkbox"/></p> <p>Site 10 <input type="checkbox"/></p> <p>Help!</p> <p>Download</p> <p>Start Again</p>	<p style="text-align: center;">Site Info:</p> <p>Predicted site 1</p> <p>Site Volume: 1394 Cubic Angstroms</p> <p>Protein Volume: 24835 Cubic Angstroms</p> <p style="text-align: center;">Binding Box Around Selected Sites</p> <p>Min Coords: (-29, 0, -22)</p> <p>Max Coords: (4, 28, 1)</p>	<p style="text-align: center;">Residues:</p> <table border="0"> <tr><td>1596</td><td>CA</td><td>GLY</td><td>A</td><td>217</td></tr> <tr><td>1597</td><td>C</td><td>GLY</td><td>A</td><td>217</td></tr> <tr><td>1598</td><td>O</td><td>GLY</td><td>A</td><td>217</td></tr> <tr><td>1599</td><td>N</td><td>PRO</td><td>A</td><td>218</td></tr> <tr><td>1600</td><td>CA</td><td>PRO</td><td>A</td><td>218</td></tr> <tr><td>1601</td><td>CD</td><td>PRO</td><td>A</td><td>218</td></tr> <tr><td>1604</td><td>C</td><td>PRO</td><td>A</td><td>218</td></tr> <tr><td>1606</td><td>N</td><td>CYS</td><td>A</td><td>219</td></tr> <tr><td>1607</td><td>CA</td><td>CYS</td><td>A</td><td>219</td></tr> <tr><td>1678</td><td>CG</td><td>LEU</td><td>A</td><td>227</td></tr> <tr><td>1680</td><td>CD2</td><td>LEU</td><td>A</td><td>227</td></tr> <tr><td>1683</td><td>N</td><td>ASN</td><td>A</td><td>228</td></tr> <tr><td>1689</td><td>C</td><td>ASN</td><td>A</td><td>228</td></tr> <tr><td>1690</td><td>O</td><td>ASN</td><td>A</td><td>228</td></tr> <tr><td>1692</td><td>CA</td><td>HIS</td><td>A</td><td>229</td></tr> <tr><td>1701</td><td>N</td><td>LEU</td><td>A</td><td>230</td></tr> </table>	1596	CA	GLY	A	217	1597	C	GLY	A	217	1598	O	GLY	A	217	1599	N	PRO	A	218	1600	CA	PRO	A	218	1601	CD	PRO	A	218	1604	C	PRO	A	218	1606	N	CYS	A	219	1607	CA	CYS	A	219	1678	CG	LEU	A	227	1680	CD2	LEU	A	227	1683	N	ASN	A	228	1689	C	ASN	A	228	1690	O	ASN	A	228	1692	CA	HIS	A	229	1701	N	LEU	A	230
1596	CA	GLY	A	217																																																																														
1597	C	GLY	A	217																																																																														
1598	O	GLY	A	217																																																																														
1599	N	PRO	A	218																																																																														
1600	CA	PRO	A	218																																																																														
1601	CD	PRO	A	218																																																																														
1604	C	PRO	A	218																																																																														
1606	N	CYS	A	219																																																																														
1607	CA	CYS	A	219																																																																														
1678	CG	LEU	A	227																																																																														
1680	CD2	LEU	A	227																																																																														
1683	N	ASN	A	228																																																																														
1689	C	ASN	A	228																																																																														
1690	O	ASN	A	228																																																																														
1692	CA	HIS	A	229																																																																														
1701	N	LEU	A	230																																																																														




FIGURE 12: Pocket-Finder results for surface cleft identification of IGFBP3. Binding site of the ligand), as predicted by the tool. The cleft colored in cyan shows a significant pocket. This pocket correlates well with the binding site as predicted by the docking tools.

3.3 Prediction analysis

Ramachandran plot analysis was done to measure the robustness of the structure. Both the structure were robust. However, IGFBP3 had a higher percentage of loop structure making it a bit less stable prediction (**FIGURE 13 AND 14**).




FIGURE 13: Ramachandran Plot for ALOX5. This plot shows that most of the scattered plots (phi vs psi) are located in the permissible region proving that the structure is a stable one.




FIGURE 14: Ramachandran Plot for IGFBP3. Although a significant amount of dots have fallen into the non permissible zone the structure is still a stable one. This may indicate that the protein has a too open conformation which is often characteristic to proteins that are designed to bind a counterpart constitutively.

4. DISCUSSION

Andrographis paniculata is reported to contain high level of silibinin. Silibinin, an active compound affects gene expression of many genes involved in cell cycle regulation, apoptosis

and tumor suppression. However the immediate binding partners were not predicted by it.

A search through STITCH 3.1 database gave a gross estimation of interaction partners. Using that data further literature search was carried

out keeping binding motifs in the focus. Few potential targets were selected and based on the docking score two protein ALOX5 and IGFBP3 showed significant binding potential with the ligand.

AutoDock used binding affinity (kcal/mole) as a binding parameter whereas PATCHDOCK has their own binding score which can often be fine-tuned using FIRDOCK on the basis of free energy information. The PATCHDOCK score for docked ligand and the macromolecules were significant enough. The high 'Area' of interaction also reveals tight binding. The ligand was bound well inside the active site cleft and no nonspecific interaction was found. Therefore, the binding of silibinin to the macromolecule definitely indicates potential of a predictive drug. PocketFinder results scoring confirmed that macromolecule forms pockets in the binding sites of the ligand and therefore rules out possibility of false positives (**FIGURE 11 AND FIGURE 12**).

AutoDock predicted binding affinity was above -8.0 and -9.0 which is quite a satisfactory one. Studies with control showed that a random binding might show around -5.0 to -6.0 binding affinity score (data not given here). This indicates that the binding was not by chance. However further confirmatory simulation was run with better exhaustiveness (default value 8.0). PocketFinder results correlated well with the docking results proving the accuracy of the model.

Important residues of ALOX5 that forms the pocket are-

GLY11, SER12, GLN13, LEU67, ASP80, CYS100, TYR101, ARG102, TRP103, ILE 104, THR 105, ASP 107, VAL108, GLU 109, VAL110, VAL111, LEU112, ARG113, HIS131, LYS134, GLU135, TRP148,

PHE152, ARG166, PHE 170, ASP171, ASn181, HIS361, GLN364, HIS368, TYR 384, ARG402, ARG412 and more.

Important residues of IGFBP3 that forms the pocket are -

GLY217, PRO218, CYS219, LEU227, ASN228, HIS229, LYS231, PHE232, ASN234, VAL235, LEU236, ARG239, GLY240, HIS242, PRO244, CYS246, GLN256, ARG257, ARG258, SER260, LYS261, ARG265, GLY266, PHE267, TYR 274 and more.

SUBCOMP search tool was used to identify structurally similar compounds. The C value of those compounds were plotted against their binding affinity and the found result indicate the potential of designing a synthetic drug more efficient as the lower c values had better binding efficiency. However this comment has to be analyzed further with concrete lab studies before concluding so.

Modern rational drug designing belongs to a twofold process. At first, potential hit are generated using approaches as carried out here. However, irrespective of values hits have to be analyzed furthermore in the molecular level physically. Despite our significant scoring values we believe the drug protein interaction will have to be further investigated physically.

Our study here should give us better insight about how the traditional use of *Andrographis paniculata* is riveted well inside science rather than folklore. We hope, this study would help in designing a more efficient rational drug in the future and also would help us collect more natural products from the plant concerned. Hence, we hope the study will assist us to understand the beauty underneath natural products, to unlock the mystery of nature itself.

5. REFERENCES

- Agarwal, C., R. P. Singh, et al. (2003). "Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells." *Oncogene* 22(51): 8271-82.
- Ahmed-Belkacem, A., N. Ahnou, et al. "Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase." *Gastroenterology* 138(3): 1112-22.
- Akbar, S. "Andrographis paniculata: a review of pharmacological activities and clinical effects." *Altern Med Rev* 16(1): 66-77.
- Alagesabooopathi, C., P. Diwakaran, et al. (1999). "Andrographis paniculata nees in tribal medicine of Tamil Nadu." *Anc Sci Life* 19(1-2): 28-30.
- Alagesabooopathi, C., P. Dwarakan, et al. (2001). "Variegated wild medicinal plant of andrographis paniculata ness (acanthaceae) recorded in kondapalli, krishna district of andhra pradesh." *Anc Sci Life* 21(1): 10-1.
- Ambrish Roy, D. X., Jonathan Poisson, Yang Zhang (2011). "A Protocol for Computer-Based Protein Structure and Function Prediction." *Journal of Visualized Experiments* 57(e3259).
- Awang, K., N. H. Abdullah, et al. "Cardiovascular Activity of Labdane Diterpenes from Andrographis paniculata in Isolated Rat Hearts." *J Biomed Biotechnol* 2012: 876458.
- Balu, S. and C. Alagesabooopathi (1993). "Anti-inflammatory activities of some species of andrographis wall. (Acanthaceae)." *Anc Sci Life* 13(1-2): 180-4.
- Borhanuddin, M., M. Shamsuzzoha, et al. (1994). "Hypoglycaemic effects of Andrographis paniculata Nees on non-diabetic rabbits." *Bangladesh Med Res Counc Bull* 20(1): 24-6.
- Burgos, R. A., J. L. Hancke, et al. (2009). "Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial." *Clin Rheumatol* 28(8): 931-46.
- Chakravarti, R. N. and D. Chakravarti (1951). "Andrographolide, the active constituent of Andrographis paniculata Nees; a preliminary communication." *Ind Med Gaz* 86(3): 96-7.
- Chandrasekaran, C. V., A. Gupta, et al. "Effect of an extract of Andrographis paniculata leaves on inflammatory and allergic mediators in vitro." *J Ethnopharmacol* 129(2): 203-7.
- Chandrasekaran, C. V., P. Thiyagarajan, et al. (2009). "Evaluation of the genotoxic potential and acute oral toxicity of standardized extract of Andrographis paniculata (KalmCold)." *Food Chem Toxicol* 47(8): 1892-902.
- Chao, W. W., Y. H. Kuo, et al. (2009). "Inhibitory effects of ethyl acetate extract of Andrographis paniculata on NF- κ B trans-activation activity and LPS-induced acute inflammation in mice." *Evid Based Complement Alternat Med*.
- Chao, W. W., Y. H. Kuo, et al. "Anti-inflammatory activity of new compounds from Andrographis paniculata by NF- κ B transactivation inhibition." *J Agric Food Chem* 58(4): 2505-12.
- Chao, W. W. and B. F. Lin "Isolation and identification of bioactive compounds in Andrographis paniculata (Chuanxinlian)." *Chin Med* 5: 17.
- Chen, L. X., G. X. Qu, et al. (2006). "[Studies on diterpenoids from Andrographis paniculata]." *Zhongguo Zhong Yao Za Zhi* 31(19): 1594-7.
- Chen, Y., D. Li, et al. (2009). "The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia." *Cell Cycle* 8(21): 3488-92.
- Cheung, C. W., P. J. Taylor, et al. (2007). "Therapeutic value of orally administered silibinin in renal cell carcinoma: manipulation of insulin-like growth factor binding protein-3 levels." *BJU Int* 100(2): 438-44.
- Cheung, C. W., D. A. Vesey, et al. (2007). "Silibinin inhibits renal cell carcinoma via mechanisms that are independent of insulin-like growth factor-binding protein 3." *BJU Int* 99(2): 454-60.
- Chien, C. F., Y. T. Wu, et al. "Herb-drug interaction of Andrographis paniculata extract and andrographolide on the pharmacokinetics of theophylline in rats." *Chem Biol Interact* 184(3): 458-65.
- Colturato, C. P., R. P. Constantin, et al. "Metabolic effects of silibinin in the rat liver." *Chem Biol Interact* 195(2): 119-32.
- Cosconati, S., S. Forli, et al. "Virtual Screening with AutoDock: Theory and Practice." *Expert Opin Drug Discov* 5(6): 597-607.
- Croft, D., G. O'Kelly, et al. "Reactome: a database of reactions, pathways and biological processes." *Nucleic Acids Res* 39(Database issue): D691-7.
- Cubbage, M. L., A. Suwanichkul, et al. (1990). "Insulin-like growth factor binding protein-3. Organization of the human chromosomal gene and demonstration of promoter activity." *J Biol Chem* 265(21): 12642-9.
- Dahari, H., J. Guedj, et al. "Silibinin mode of action against hepatitis C virus: a controversy yet to be resolved." *Hepatology* 54(2): 749.
- Das, S., N. Gautam, et al. (2009). "Oxidative stress in the brain of nicotine-induced toxicity: protective role

- of *Andrographis paniculata* Nees and vitamin E." *Appl Physiol Nutr Metab* 34(2): 124-35.
- Dehmlow, C., J. Erhard, et al. (1996). "Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin." *Hepatology* 23(4): 749-54.
 - Eurich, D., M. Bahra, et al. "Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy." *Exp Clin Transplant* 9(1): 1-6.
 - Fan, S., M. Qi, et al. "P53 activation plays a crucial role in silibinin induced ROS generation via PUMA and JNK." *Free Radic Res* 46(3): 310-9.
 - Fan, S., Y. Yu, et al. "P53-mediated GSH depletion enhanced the cytotoxicity of NO in silibinin-treated human cervical carcinoma HeLa cells." *Free Radic Res*.
 - Funk, C. D., S. Hoshiko, et al. (1989). "Characterization of the human 5-lipoxygenase gene." *Proc Natl Acad Sci U S A* 86(8): 2587-91.
 - Geethangili, M., Y. K. Rao, et al. (2008). "Cytotoxic constituents from *Andrographis paniculata* induce cell cycle arrest in jurkat cells." *Phytother Res* 22(10): 1336-41.
 - Girish, C. P. C. (2006). "Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine." *Indian Journal of Medical Research* 124: 491-504.
 - Goodsell, D. S. (2009). "Computational docking of biomolecular complexes with AutoDock." *Cold Spring Harb Protoc* 2009(5): pdb prot5200.
 - Goodsell, D. S., G. M. Morris, et al. (1996). "Automated docking of flexible ligands: applications of AutoDock." *J Mol Recognit* 9(1): 1-5.
 - Guex, N. and M. C. Peitsch (1997). "SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling." *Electrophoresis* 18(15): 2714-23.
 - Haddad, Y., D. Vallerand, et al. (2009). "Antioxidant and Hepatoprotective Effects of Silibinin in a Rat Model of Nonalcoholic Steatohepatitis." *Evid Based Complement Alternat Med*.
 - Handa, S. S. and A. Sharma (1990). "Hepatoprotective activity of andrographolide from *Andrographis paniculata* against carbontetrachloride." *Indian J Med Res* 92: 276-83.
 - Hoshiko, S., O. Radmark, et al. (1990). "Characterization of the human 5-lipoxygenase gene promoter." *Proc Natl Acad Sci U S A* 87(23): 9073-7.
 - Hruby, K., G. Csomos, et al. (1983). "Chemotherapy of *Amanita phalloides* poisoning with intravenous silibinin." *Hum Toxicol* 2(2): 183-95.
 - Huang, S. Y. and X. Zou (2006). "An iterative knowledge-based scoring function to predict protein-ligand interactions: I. Derivation of interaction potentials." *J Comput Chem* 27(15): 1866-75.
 - Huang, S. Y. and X. Zou (2006). "An iterative knowledge-based scoring function to predict protein-ligand interactions: II. Validation of the scoring function." *J Comput Chem* 27(15): 1876-82.
 - Jasper, H., P. Pennisi, et al. (1999). "Evaluation of disease activity by IGF-I and IGF binding protein-3 (IGFBP3) in acromegaly patients distributed according to a clinical score." *J Endocrinol Invest* 22(1): 29-34.
 - Jayaprakasam, B., D. Gunasekar, et al. (2001). "Androechin, a new chalcone glucoside from *Andrographis echioides*." *J Asian Nat Prod Res* 3(1): 43-8.
 - Jonathan H. Chen, E. L., S. Joshua Swamidass, Dennis Wang and Pierre Baldi* (2007). "ChemDB update—full-text search and virtual chemical space." *Oxford Journals* 23(12): 2348-2351.
 - Jung, H. J., J. W. Park, et al. (2009). "Silibinin inhibits expression of HIF-1alpha through suppression of protein translation in prostate cancer cells." *Biochem Biophys Res Commun* 390(1): 71-6.
 - Kapil, A., I. B. Koul, et al. (1993). "Antihepatotoxic effects of major diterpenoid constituents of *Andrographis paniculata*." *Biochem Pharmacol* 46(1): 182-5.
 - KEGGPathwayDatabase "Reaction R01595 and R03058 at."
 - Kennedy, B. P., R. E. Diehl, et al. (1991). "Gene characterization and promoter analysis of the human 5-lipoxygenase-activating protein (FLAP)." *J Biol Chem* 266(13): 8511-6.
 - Kesava Reddy, M., M. Vijaya Bhaskar Reddy, et al. (2003). "A new chalcone and a flavone from *Andrographis neesiana*." *Chem Pharm Bull (Tokyo)* 51(7): 854-6.
 - Kesava Reddy, M., M. Vijaya Bhaskar Reddy, et al. (2003). "Two new flavonoids from *Andrographis rothii*." *Chem Pharm Bull (Tokyo)* 51(2): 191-3.
 - Kim, S., S. H. Kim, et al. (2009). "Silibinin prevents TPA-induced MMP-9 expression by down-regulation of COX-2 in human breast cancer cells." *J Ethnopharmacol* 126(2): 252-7.
 - Kim, S. H., J. H. Choi, et al. (2005). "Leukotriene-related gene polymorphisms in patients with aspirin-intolerant urticaria and aspirin-intolerant asthma: differing contributions of ALOX5 polymorphism in Korean population." *J Korean Med Sci* 20(6): 926-31.
 - Kim, Y. C., E. J. Kim, et al. (2003). "Comparative bioavailability of silibinin in healthy male volunteers." *Int J Clin Pharmacol Ther* 41(12): 593-6.

- Koteswara Rao, Y., G. Vimalamma, et al. (2004). "Flavonoids and andrographolides from *Andrographis paniculata*." *Phytochemistry* 65(16): 2317-21.
- Kuhn, M., C. von Mering, et al. (2008). "STITCH: interaction networks of chemicals and proteins." *Nucleic Acids Res* 36(Database issue): D684-8.
- Kumar, R. A., K. Sridevi, et al. (2004). "Anticancer and immunostimulatory compounds from *Andrographis paniculata*." *J Ethnopharmacol* 92(2-3): 291-5.
- Laskowski, R. A., J. A. Rullmann, et al. (1996). "AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR." *J Biomol NMR* 8(4): 477-86.
- Li, M., X. Y. Zhou, et al. "[Allelopathy of *Andrographis paniculata* vegetative]." *Zhong Yao Cai* 33(12): 1829-33.
- Lin, C. J., R. Sukarieh, et al. (2009). "Silibinin inhibits translation initiation: implications for anticancer therapy." *Mol Cancer Ther* 8(6): 1606-12.
- Lin, F. L., S. J. Wu, et al. (2009). "Antioxidant, antioedema and analgesic activities of *Andrographis paniculata* extracts and their active constituent andrographolide." *Phytother Res* 23(7): 958-64.
- Liu, J., Z. T. Wang, et al. (2008). "Andrograpanin, isolated from *Andrographis paniculata*, exhibits anti-inflammatory property in lipopolysaccharide-induced macrophage cells through down-regulating the p38 MAPKs signaling pathways." *Int Immunopharmacol* 8(7): 951-8.
- Lovett-Racke, A. E., P. Bittner, et al. (1998). "Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3)." *J Clin Invest* 101(8): 1797-804.
- Maiti, K., K. Mukherjee, et al. "Enhancing bioavailability and hepatoprotective activity of andrographolide from *Andrographis paniculata*, a well-known medicinal food, through its herbosome." *J Sci Food Agric* 90(1): 43-51.
- Mandal, S. C., A. K. Dhara, et al. (2001). "Studies on psychopharmacological activity of *Andrographis paniculata* extract." *Phytother Res* 15(3): 253-6.
- Manev, H. and R. Manev (2006). "5-Lipoxygenase (ALOX5) and FLAP (ALOX5AP) gene polymorphisms as factors in vascular pathology and Alzheimer's disease." *Med Hypotheses* 66(3): 501-3.
- Mashlach, E., D. Schneidman-Duhovny, et al. "An integrated suite of fast docking algorithms." *Proteins* 78(15): 3197-204.
- Mishra, U. S., A. Mishra, et al. (2009). "Antibacterial Activity of Ethanol Extract of *Andrographis paniculata*." *Indian J Pharm Sci* 71(4): 436-8.
- Mkrtchyan, A., V. Panosyan, et al. (2005). "A phase I clinical study of *Andrographis paniculata* fixed combination Kan Jang versus ginseng and valerian on the semen quality of healthy male subjects." *Phytomedicine* 12(6-7): 403-9.
- Morris, G. M., R. Huey, et al. (2008). "Using AutoDock for ligand-receptor docking." *Curr Protoc Bioinformatics* Chapter 8: Unit 8 14.
- Nagalekshmi, R., A. Menon, et al. "Hepatoprotective activity of *Andrographis paniculata* and *Swertia chirayita*." *Food Chem Toxicol* 49(12): 3367-73.
- Natsuzaka, M., S. Naganuma, et al. "Hypoxia induces IGFBP3 in esophageal squamous cancer cells through HIF-1 α -mediated mRNA transcription and continuous protein synthesis." *FASEB J*.
- Neogy, S., S. Das, et al. (2008). "Amelioratory effect of *Andrographis paniculata* Nees on liver, kidney, heart, lung and spleen during nicotine induced oxidative stress." *Environ Toxicol Pharmacol* 25(3): 321-8.
- Neumann, U. P., M. Biermer, et al. "Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy." *J Hepatol* 52(6): 951-2.
- Nielsen, M., C. Lundegaard, et al. (2010). "CPHmodels-3.0—remote homology modeling using structure-guided sequence profiles." *Nucleic Acids Research* 38(suppl 2): W576.
- Ojha, S., S. Bharti, et al. "*Andrographis paniculata* extract protect against isoproterenol-induced myocardial injury by mitigating cardiac dysfunction and oxidative injury in rats." *Acta Pol Pharm* 69(2): 269-78.
- Ojha, S. K., S. Bharti, et al. "Protective effect of hydroalcoholic extract of *Andrographis paniculata* on ischaemia-reperfusion induced myocardial injury in rats." *Indian J Med Res* 135(3): 414-21.
- Oleg Trott, A. J. O. (Journal of Computational Chemistry). "AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading." 31(2): 455-461.
- Pan, Y., B. A. Abd-Rashid, et al. "In vitro modulatory effects of *Andrographis paniculata*, *Centella asiatica* and *Orthosiphon stamineus* on cytochrome P450 2C19 (CYP2C19)." *J Ethnopharmacol* 133(2): 881-7.
- Panossian, A., A. Hovhannisyanyan, et al. (2000). "Pharmacokinetic and oral bioavailability of andrographolide from *Andrographis paniculata* fixed combination Kan Jang in rats and human." *Phytomedicine* 7(5): 351-64.
- Parichatikanond, W., C. Suthisisang, et al. "Study of anti-inflammatory activities of the pure compounds from *Andrographis paniculata* (burm.f.) Nees and their

- effects on gene expression." *Int Immunopharmacol* 10(11): 1361-73.
- Pekthong, D., N. Blanchard, et al. (2009). "Effects of Andrographis paniculata extract and Andrographolide on hepatic cytochrome P450 mRNA expression and monooxygenase activities after in vivo administration to rats and in vitro in rat and human hepatocyte cultures." *Chem Biol Interact* 179(2-3): 247-55.
 - Pholphana, N., N. Rangkadilok, et al. (2004). "Determination and variation of three active diterpenoids in Andrographis paniculata (Burm.f.) Nees." *Phytochem Anal* 15(6): 365-71.
 - Povelitsa, E. A. (2007). "[Insulin-like factor of growth (IGFI), insulin-like growth factor binding protein 3 (IGFBP3) and transforming growth factor beta1 (TGF-beta1) in patients with locally-advanced and metastatic cancer of prostate]." *Vopr Onkol* 53(5): 544-8.
 - Puri, A., R. Saxena, et al. (1993). "Immunostimulant agents from Andrographis paniculata." *J Nat Prod* 56(7): 995-9.
 - Qizhen, D., G. Jerz, et al. (2003). "Separation of andrographolide and neoandrographolide from the leaves of Andrographis paniculata using high-speed counter-current chromatography." *J Chromatogr A* 984(1): 147-51.
 - Rajani, M., N. Shrivastava, et al. (2000). "A rapid method for isolation of andrographolide from andrographis paniculata nees (kalmegh)." *Pharm Biol* 38(3): 204-9.
 - Rao, Y. K., A. G. Damu, et al. (2003). "Flavonoids from Andrographis viscosula." *Chem Pharm Bull (Tokyo)* 51(12): 1374-6.
 - Rao, Y. K., P. Harikishore, et al. (2002). "Flavones from Andrographis viscosula." *Phytochemistry* 61(8): 927-9.
 - Rattanachaikunsopon, P. and P. Phumkhachorn (2009). "Prophylactic effect of Andrographis paniculata extracts against Streptococcus agalactiae infection in Nile tilapia (Oreochromis niloticus)." *J Biosci Bioeng* 107(5): 579-82.
 - Regel, I., M. Eichenmuller, et al. "IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors." *Mol Cancer* 11(1): 9.
 - Reyes, B. A., N. D. Bautista, et al. (2006). "Anti-diabetic potentials of Momordica charantia and Andrographis paniculata and their effects on estrous cyclicity of alloxan-induced diabetic rats." *J Ethnopharmacol* 105(1-2): 196-200.
 - Roy, A., A. Kucukural, et al. "I-TASSER: a unified platform for automated protein structure and function prediction." *Nat Protoc* 5(4): 725-38.
 - Roy, A., A. Kucukural, et al. (2010). "I-TASSER: a unified platform for automated protein structure and function prediction." *Nat Protoc* 5(4): 725-738.
 - Salamone, F., F. Galvano, et al. "Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis." *Dig Liver Dis* 44(4): 334-42.
 - Samuelsson, B., S. Hoshiko, et al. (1991). "Characterization of the promoter of the human 5-lipoxygenase gene." *Adv Prostaglandin Thromboxane Leukot Res* 21A: 1-8.
 - Schildkraut, J. M., W. Demark-Wahnefried, et al. (2005). "IGF1 (CA)19 repeat and IGFBP3 -202 A/C genotypes and the risk of prostate cancer in Black and White men." *Cancer Epidemiol Biomarkers Prev* 14(2): 403-8.
 - Schneidman-Duhovny, D., Y. Inbar, et al. (2005). "PatchDock and SymmDock: servers for rigid and symmetric docking." *Nucleic Acids Res* 33(Web Server issue): W363-7.
 - Schneidman-Duhovny D, I. Y., Polak V, Shatsky M, Halperin I, Benyamini H, Barzilai A, Dror O, Haspel N, Nussinov R, Wolfson HJ (2003). "Taking geometry to its edge: fast unbound rigid (and hinge-bent) docking. Proteins." *Proteins* 52(1): 107-12.
 - Seeliger, D. and B. L. de Groot "Ligand docking and binding site analysis with PyMOL and Autodock/Vina." *J Comput Aided Mol Des* 24(5): 417-22.
 - Sheeja, K., C. Guruvayoorappan, et al. (2007). "Antiangiogenic activity of Andrographis paniculata extract and andrographolide." *Int Immunopharmacol* 7(2): 211-21.
 - Sheeja, K. and G. Kuttan (2006). "Ameliorating effects of Andrographis paniculata extract against cyclophosphamide-induced toxicity in mice." *Asian Pac J Cancer Prev* 7(4): 609-14.
 - Singh, R. P. and R. Agarwal (2006). "Prostate cancer chemoprevention by silibinin: bench to bedside." *Mol Carcinog* 45(6): 436-42.
 - Singh, R. P., S. Banerjee, et al. (2001). "Modulatory influence of Andrographis paniculata on mouse hepatic and extrahepatic carcinogen metabolizing enzymes and antioxidant status." *Phytother Res* 15(5): 382-90.
 - Singh, R. P., G. Deep, et al. (2007). "Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft." *Carcinogenesis* 28(12): 2567-74.
 - Singha, P. K., S. Roy, et al. (2003). "Antimicrobial activity of Andrographis paniculata." *Fitoterapia* 74(7-8): 692-4.
 - Stein, L. D. (2004). "Using the Reactome database." *Curr Protoc Bioinformatics Chapter 8: Unit 8 7*.

- Sulaiman, M. R., Z. A. Zakaria, et al. "Antinociceptive and antiedematogenic activities of andrographolide isolated from *Andrographis paniculata* in animal models." *Biol Res Nurs* 11(3): 293-301.
- Szklarczyk, D., A. Franceschini, et al. "The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored." *Nucleic Acids Res* 39(Database issue): D561-8.
- Tiwari, R., K. Mahasenan, et al. (2009). "Carborane clusters in computational drug design: a comparative docking evaluation using AutoDock, FlexX, Glide, and Surfex." *J Chem Inf Model* 49(6): 1581-9.
- Trivedi, N. P. and U. M. Rawal (2001). "Hepatoprotective and antioxidant property of *Andrographis paniculata* (Nees) in BHC induced liver damage in mice." *Indian J Exp Biol* 39(1): 41-6.
- Tyagi, A. K., C. Agarwal, et al. (2003). "Silibinin down-regulates survivin protein and mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papilloma RT4 cells." *Biochem Biophys Res Commun* 312(4): 1178-84.
- Verma, N. and M. Vinayak (2008). "Antioxidant action of *Andrographis paniculata* on lymphoma." *Mol Biol Rep* 35(4): 535-40.
- Vogel, G., B. Tuchweber, et al. (1984). "Protection by silibinin against *Amanita phalloides* intoxication in beagles." *Toxicol Appl Pharmacol* 73(3): 355-62.
- von Schonfeld, J., B. Weisbrod, et al. (1997). "Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity." *Cell Mol Life Sci* 53(11-12): 917-20.
- Wang, D. W. and H. Y. Zhao (1994). "Prevention of atherosclerotic arterial stenosis and restenosis after angioplasty with *Andrographis paniculata* nees and fish oil. Experimental studies of effects and mechanisms." *Chin Med J (Engl)* 107(6): 464-70.
- Wang, H. J., S. Tashiro, et al. (2008). "Inhibition of insulin-like growth factor 1 receptor signaling enhanced silibinin-induced activation of death receptor and mitochondrial apoptotic pathways in human breast cancer MCF-7 cells." *J Pharmacol Sci* 107(3): 260-9.
- Wang, Q., Y. Ye, et al. "Dual effects of silibinin treatment on autophagy-regulated dermal apoptosis retardation and epidermal apoptosis up-regulation in UVB-induced skin inflammation." *J Asian Nat Prod Res*.
- Wu, Y. C., B. R. Buckner, et al. "Elevated IGFBP3 levels in diabetic tears: a negative regulator of IGF-1 signaling in the corneal epithelium." *Ocul Surf* 10(2): 100-7.
- Xu, C. and Z. T. Wang "[Chemical constituents from roots of *Andrographis paniculata*]." *Yao Xue Xue Bao* 46(3): 317-21.
- Yoopan, N., P. Thisoda, et al. (2007). "Cardiovascular effects of 14-deoxy-11,12-didehydroandrographolide and *Andrographis paniculata* extracts." *Planta Med* 73(6): 503-11.
- Zhang, T. (2000). "[Advances in the study of *Andrographis paniculata* (Burm.f.) Nees]." *Zhong Yao Cai* 23(6): 366-8.
- Zhang, X. F. and B. K. Tan (2000). "Anti-diabetic property of ethanolic extract of *Andrographis paniculata* in streptozotocin-diabetic rats." *Acta Pharmacol Sin* 21(12): 1157-64.
- Zhang, X. F. and B. K. Tan (2000). "Antihyperglycaemic and anti-oxidant properties of *Andrographis paniculata* in normal and diabetic rats." *Clin Exp Pharmacol Physiol* 27(5-6): 358-63.
- Zhang, Y. (2008). "I-TASSER server for protein 3D structure prediction." *BMC Bioinformatics* 9: 40.
- Zhang, Y., Q. Li, et al. "Silibinin Triggers Apoptosis and Cell-Cycle Arrest of SGC7901 Cells." *Phytother Res*.
- Zhang, Y. Z., J. Z. Tang, et al. (1994). "[Study of *Andrographis paniculata* extracts on antiplatelet aggregation and release reaction and its mechanism]." *Zhongguo Zhong Xi Yi Jie He Za Zhi* 14(1): 28-30, 34, 5.
- Zi, X., J. Zhang, et al. (2000). "Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells." *Cancer Res* 60(20): 5617-20.



***Corresponding Author:**

Aubhishek Zaman*

*Department of Genetic Engineering and Biotechnology,
University of Dhaka, Dhaka-1000, BANGLADESH*